Defence Therapeutics
Defence Therapeutics Inc. is a Canadian biotechnology company focused on developing next-generation vaccines and antibody-drug conjugate (ADC) products using its proprietary platform, ACCUM™ technology. The company aims to create effective treatments for catastrophic illnesses such as cancer and infectious diseases through precision delivery of vaccine antigens and ADCs, enhancing efficacy and potency. With a strong focus on innovation, strategic products, and collaborations, Defence Therapeutics is pioneering advances in immuno-oncology, drug delivery technologies, and radiopharmaceuticals.
Industries
Nr. of Employees
small (1-50)
Defence Therapeutics
Vancouver, British Columbia, Canada, North America
Products
Nuclear-localizing delivery platform (proprietary)
Delivery platform designed to facilitate endosomal escape and transport payloads to the nucleus, increasing intracellular accumulation and creating an intracellular reservoir for controlled payload release.
Optimized endosomal-disrupting anticancer molecule (preclinical)
Chemically optimized molecule derived from the delivery platform exhibiting direct anticancer activity in preclinical models when administered intratumorally or via inhalation routes.
Vaccine platform and antigen‑admix vaccine formulations (preclinical)
Vaccine candidates combining antigen formulations with a delivery moiety to enhance antigen presentation, induce durable memory responses, and treat established tumors in preclinical models; results include peer‑reviewed demonstration of prophylactic protection, antibody-mediated functional activity in vitro, therapeutic synergy with checkpoint inhibitors, and GLP safety/immunogenicity data.
LNP mRNA vaccine formulations (preclinical)
Lipid nanoparticle mRNA vaccine formulations developed with the delivery approach that produced increased antibody responses in preclinical comparisons to standard mRNA formulations.
Nuclear-localizing delivery platform (proprietary)
Delivery platform designed to facilitate endosomal escape and transport payloads to the nucleus, increasing intracellular accumulation and creating an intracellular reservoir for controlled payload release.
Optimized endosomal-disrupting anticancer molecule (preclinical)
Chemically optimized molecule derived from the delivery platform exhibiting direct anticancer activity in preclinical models when administered intratumorally or via inhalation routes.
Vaccine platform and antigen‑admix vaccine formulations (preclinical)
Vaccine candidates combining antigen formulations with a delivery moiety to enhance antigen presentation, induce durable memory responses, and treat established tumors in preclinical models; results include peer‑reviewed demonstration of prophylactic protection, antibody-mediated functional activity in vitro, therapeutic synergy with checkpoint inhibitors, and GLP safety/immunogenicity data.
LNP mRNA vaccine formulations (preclinical)
Lipid nanoparticle mRNA vaccine formulations developed with the delivery approach that produced increased antibody responses in preclinical comparisons to standard mRNA formulations.
Services
Preclinical study design and execution
Design and conduct of in vitro and in vivo efficacy studies in multiple tumor models to evaluate immunogenicity, tumor control, antibody function, cellular mechanisms (dendritic cell cross-presentation and CD8+ T cells), and combination strategies with checkpoint inhibitors; includes GLP study execution for safety and immunogenicity.
cGMP manufacturing and final product optimization for Phase I
cGMP process development, execution of manufacturing dry runs, and final drug product optimization with quality-control steps to support Phase I clinical trials and filings.
Regulatory and clinical trial enabling support
Advisory and submission support for clinical trial applications (IND/CTA) and interactions with regulatory authorities to enable initiation of first‑in‑human studies.
Partnership and licensing facilitation
Program management and negotiation support for collaborative research, development partnerships, and licensing arrangements to advance technologies to partners and sponsors.
Preclinical study design and execution
Design and conduct of in vitro and in vivo efficacy studies in multiple tumor models to evaluate immunogenicity, tumor control, antibody function, cellular mechanisms (dendritic cell cross-presentation and CD8+ T cells), and combination strategies with checkpoint inhibitors; includes GLP study execution for safety and immunogenicity.
cGMP manufacturing and final product optimization for Phase I
cGMP process development, execution of manufacturing dry runs, and final drug product optimization with quality-control steps to support Phase I clinical trials and filings.
Regulatory and clinical trial enabling support
Advisory and submission support for clinical trial applications (IND/CTA) and interactions with regulatory authorities to enable initiation of first‑in‑human studies.
Partnership and licensing facilitation
Program management and negotiation support for collaborative research, development partnerships, and licensing arrangements to advance technologies to partners and sponsors.
Expertise Areas
- Drug delivery platform development (nuclear-localizing approaches)
- Antibody-drug conjugate (ADC) design and optimization
- Vaccine development (protein and mRNA modalities)
- Preclinical immuno‑oncology and murine tumor-model studies
Key Technologies
- Nuclear‑localizing delivery mechanisms
- Antibody‑drug conjugation techniques
- Endosomal escape / membrane‑disrupting moieties
- Lipid nanoparticle (LNP) mRNA delivery